Incannex Healthcare Inc. — fact timeline

Incannex Healthcare Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).

“March 16, 2026, Incannex Healthcare Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the bid price deficiency under Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Rule"), which the Company previously reported on in its Current Reports on Form 8-K filed on April 23, 2025 and Form 8-K filed on October 21, 2025, has been cured, and that the Company is now in compliance with the Minimum Bid Price Rule.”

Incannex Healthcare Inc. terminated Sales Agreement with Curvature Securities, LLC and A.G.P./Alliance Global Partners valued at Aggregate gross proceeds of approximately $108.4 million; termination at will with no penalty (effective 2026-03-11).

“On March 11, 2026, the Company and the Sales Agents mutually agreed to terminate the Sales Agreement, effective immediately.”

Incannex Healthcare Inc. entered into Placement Agent Agreement with Curvature Securities, LLC (effective 2026-03-12).

“On March 12, 2026, the Company entered into a placement agency agreement (the “Placement Agent Agreement”) with Curvature Securities, LLC (“Curvature” or the “Placement Agent”) pursuant to which the Company engaged Curvature as the sole placement agent in connection with the Offering.”

Incannex Healthcare Inc. entered into Securities Purchase Agreement with certain institutional investors valued at approximately $10 million (effective 2026-03-12).

“On March 12, 2026, Incannex Healthcare Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors (the “Investors”), pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “Offering”) by the Company directly to the Investors (the “Registered Offering”), (i) an aggregate of 1,997,285 shares of its common stock, par value $0.0001 per share (such shares, the “Shares”; such stock, the “Common Stock”), (ii) pre-funded warrants to purchase up to 2,715 shares of its Common Stock (the “Pre-Funded Warrants”), and (iii) common stock warrants to purchase up to 2,000,000 shares of its common stock (the “Common Warrants”) at a combined purchase price of $5.0 per Share and accompanying Common Warrant, or $4.9999 per Pre-Funded Warrant and accompanying Common Warrant.”

Incannex Healthcare Inc. issued common stock.

“Incannex Announces Reverse Stock Split Incannex’s common stock is expected to begin trading on a post-split adjusted basis on February 27, 2026”

Incannex Healthcare Inc.: Amended certificate of incorporation to effect a 1-for-30 reverse stock split (effective 2026-02-26).

“On February 24, 2026, Incannex Healthcare Inc. (the “Company”) filed with the Secretary of State of the State of Delaware an amendment (the “Certificate of Amendment”) to its amended and restated certificate of incorporation, as amended (the “Certificate of Incorporation”), to effect a reverse stock split of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a ratio of 1-for-30 (the “Reverse Stock Split”).”

Incannex Healthcare Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5450(a)(1), 5810(c)(3)(A)).

“April 20, 2026 (the “Second Grace Period”) to regain compliance with the Bid Price Requirement. According to the notification from Nasdaq, the Staff’s determination was based on (i) the Company meeting the continued listing requirement for market value of its publicly held shares and all other Nasdaq initial listing standards, with the exception of the Bid Price Requirement, and (ii) the Company’s written notice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. If at any time during this Second Grace Period”

Incannex Healthcare Inc.: Amended Certificate of Incorporation to increase authorized common shares from 100,000,000 to 800,000,000 (effective 2025-05-27).

“On May 27, 2025, the Company filed with the Secretary of State of the State of Delaware an amendment to the Certificate of Incorporation to increase the authorized shares of common stock of the Company from 100,000,000 shares to 800,000,000 shares”

Incannex Healthcare Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5810(c)(3)(A)).

“to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”). This Notice is only a notification of a deficiency and has no immediate effect on the listing of the Company’s common stock, which continues to trade on The Nasdaq Global Market under the symbol “IXHL.” Pursuant to Nasdaq Listing Rule 5810(c)(3)(A) (the “Compliance Period Rule”), the Company has been provided an initial period of 180 calendar days, or until October 20, 2025 (the “Compliance Date”), to regain compliance with the Bid Price Requirement. To regain compliance, the closing bid price of the Company’s Common Stock must m”

Incannex Healthcare Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).

“January 3, 2025, Incannex Healthcare Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Company is not in compliance with Nasdaq Listing Rule 5450(b)(2)(A) (the “Listing Rule”), which requires the Company to maintain a minimum Market Value of Listed Securities (“MVLS”) of at least $50.0 million. The Notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s securities on the”

Incannex Healthcare Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).

“January 3, 2025, Incannex Healthcare Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company”

Luigi M. Barbato, M.D. was appointed as Chief Medical Officer at Incannex Healthcare Inc..

“Effective October 21, 2024 (the “Effective Date”), Incannex Healthcare Inc. (the “Company”) entered into an employment agreement (the “Employment Agreement”) with Luigi M. Barbato, M.D., to serve as the Company’s Chief Medical Officer.”

Joseph Swan was appointed as Chief Financial Officer and Secretary at Incannex Healthcare Inc..

“The Company’s Board of Directors has appointed Joseph Swan, the current Treasurer and Controller of the Company, as its Chief Financial Officer and Secretary effective as of February 29, 2024.”

Madhukar Bhalla resigned as Chief Financial Officer and Secretary at Incannex Healthcare Inc..

“Madhukar Bhalla, Chief Financial Officer and Secretary of Incannex Healthcare Inc. (the “Company”), recently notified the Company of his decision to resign from his positions effective as of February 28, 2024.”

Incannex Healthcare Inc. engaged Grant Thornton Audit Pty Ltd as its auditor.

“On December 14, 2023, the Company appointed Grant Thornton Audit Pty Ltd (“Grant Thornton”) as its independent registered public accounting firm”

PKF Brisbane Audit resigned as auditor of Incannex Healthcare Inc..

“On December 14, 2023, the Company accepted PKF’s resignation as the Company’s independent registered public accounting firm”

Incannex Healthcare Inc. underwent a change of control involving Incannex Healthcare Limited.

“the redomiciliation (“Redomiciliation”) of Incannex Healthcare Limited, an Australian corporation (“Incannex Australia”), was implemented under Australian law in accordance with the Scheme Implementation Deed”